Genetic allogenization of malignant melanoma

Transfusion Science

Volumn 17, Issue 1, 1996, Pages 169-174

  Silver, Hulbert K B ^a   Klasa, Richard J ^a   Bally, Marcel B ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; UNCLASSIFIED DRUG; VCL 1005;

CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; INJECTION PAIN; MELANOMA; PLASMID;

EID: 0029942643     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/0955-3886(95)00070-4     Document Type: Conference Paper

References (30)

1. Coca AF, Dorrance GM, Lebredo MG: Vaccination in cancer: report of the results of vaccination therapy as applied to seventy-nine cases of human cancer. Immun Exp Ther 1912; 13:543.
2. Morton D, Nizze A, Hoon D, Foshag L, Famatiga E, Gupta R, Irie R, Ramming K: Improved survival of advanced stage IV melanoma following active immunotherapy: correlation with immune response to melanoma vaccine. Proc Amer Assoc Clin Oncol 1993; 12:391.
3. Livingston PO, Takeyama H, Pollack MS, Houghton AN, Albino A, Pinsky CM, Oettgen HF, Old LJ: Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 1983; 31: 567-575.
4. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immune-potentiating effects of cyclophosphamide. Cancel Invest 1988; 6: 335-347.
5. Mitchell MS, Boswell WD, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Dean G, Stevenson L: Active specific immunotherapy for melanoma. J Clin Oncol 1990; 8:856-869.
6. Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JC: Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 1988; 61:1065-1070.
7. Rosenberg SA, Abersold P, Cornetta K, Kasid A, Morgan A, Moen R, Karson E, Lotze MT, et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumorinfiltrating lymphocytes modified by retroviral gene transaction. N Engl J Med 1990; 323:570-578.
8. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytologic T lymphocytes. J Exp Med 1994; 179:921-930.
9. Weber JS, Rosenberg SA: Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. MHC I transduction. J Natl Canc Inst 1990; 82:755-761.
10. Hui K, Grosveld F, Festenstein H: Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984; 311:750-752.
11. Hui K: Induction of tumour-specific immunity by manipulating the expression of major histocompatibility complex molecules on tumour cells. FEMS Microbiol Immunol 1990; 64:215-222.
12. Cole GA, Clements VK, Garcia EP, Ostrand-Rosenberg S: Allogeneic H-2 antigen expression is insufficient for tumor rejection. Proc Natl Acad Sci USA 1987; 4:8613.
13. Nabel E, Plautz G, Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249:1284-1288.
14. Gallagher RP, Ma B, McLean DI: Trends in basal cell carcinoma, squamous cell carcinoma and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol 1990; 23:413-421.
15. Silver HKB, Murray RN, Worth AJ, et al.: Prediction of malignant melanoma recurrence by serum N-acetylneuraminic acid. Int J Cancer 1983; 31:39-43.
16. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-908.
17. Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AHG, Prentice R, Silver HKB, Willan AR, Wilson K, Zee B: Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991; 9:729-735.
18. Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. Cancer Treat Rev 1974; 1:285-304.
19. McClay EF, Mastrangelo MJ, Bellet RE, Berd D: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71:465-469.
20. Grimm EA, Silver HKB, Roth JA, Chee DO, Morton DL: Detection of tumor associated antigen in human melanoma cell-line supernatants. Int J Cancer 1976; 17:559-564.
21. Gupta RK, Silver HKB, Reisfeld R, Morton DL: Isolation and immunochemical characterization of antibodies from sera of cancer patients reactive against human melanoma cell membranes by affinity chromatography. Cancer Res 1979; 39:1683-1695.
22. Silver HKB: The use of alpha interferon in the management of malignant melanoma, in, Gold P (ed): Interferons Yesterday, Today, and Tomorrow. New Jersey: Parthenon, 1988, pp. 30-35.
23. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FR, Leitman S, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-597.
24. Klasa RJ, Silver HKB, Dong S: In vivo induction of lymphokine-activated killer cells by Interleukin-2 splenic artery perfusion in advanced malignancy. Cancer Res 1990; 50:4906.
25. Lew D, Parker SE, Latimer T, Abai AM, Kuwahara-Rundell A, Doh SG, et al.: Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Human Gene Therapy 1995; 6:553-564.
26. Horn NA, Meek JA, Budahazi G, Marquet M: Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Human Gene Therapy 1995; 6:565-573.
27. Norman JA, Parker S, Lew D, Manthorpe M, Marquet M (editorial): Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial. Human Gene Therapy 1995, 6:549-550.
28. Ledley FD [editorial]: Assessing risk. Human Gene Therapy 1995; 6:551-552.
29. Stopeck AT, Hersh EM, Akporiaye ET, Grogan T, Harris DT, Schluter S, et al.: Phase I study of immunotherapy of malignant melanoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Proc ASCO 1995; 14:227.
30. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB: Formation of hydrophobic complexes between cationic lipids and plasmid DNA. Submitted.